PIK3CA and prostate cancer: This important study identified a reciprocal feedback loop exists between the PI3K and AR signaling pathways, and that relative to monotherapy, combined dactolisib and enzalutamide (MDV3100) treatment shows superior efficacy in both a Pten-deficient murine prostate cancer model and human prostate cancer xenografts [181].